Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05041127 · ClinicalTrials.gov registry record · Phase 2
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
A Phase 2 study of Chordoma and Metastatic Chordoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT05041127: Active Phase 2 study of Chordoma and Metastatic Chordoma, sponsored by M.D. Anderson Cancer Center.
NCT05041127 is a Phase 2 study of Chordoma and Metastatic Chordoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 29 participants, below the 85-participant average among 15 other Chordoma trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05041127, a Phase 2 study of Chordoma and Metastatic Chordoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multicenter, single arm, phase 2 study designed to evaluate the efficacy and safety of cetuximab for the treatment of advanced (unresectable)/metastatic, chordoma. The target patient population will be any chordoma patient 18 years of age with locally unresectable disease or metastatic disease.
Primary Outcome
Measured by Response Evaluation Criteria in Solid Tumors 1.1. Will be estimated based on a binomial portion expressed as percentage with 95% confidence intervals.
Conditions Studied
Interventions
- BIOLOGICAL Cetuximab
- OTHER Questionnaire Administration
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 2 |
What the registry record for NCT05041127 still lists
NCT05041127 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 85-participant average among 15 other Chordoma trials with a reported enrollment target (66% lower).
The record links to 3 conditions, with Chordoma appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT05041127 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05041127 about?
NCT05041127 is a clinical study titled "Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma". This is a multicenter, single arm, phase 2 study designed to evaluate the efficacy and safety of cetuximab for the treatment of advanced (unresectable)/metastatic, chordoma. The target patient population will be any chordoma patient 18 years of age with locally unresectable disease or metastatic dis...
What is the current status of trial NCT05041127?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2022-05-27. Estimated completion is 2026-09-01.
What conditions does trial NCT05041127 study?
This clinical trial studies the following conditions: Chordoma, Metastatic Chordoma, Unresectable Chordoma.
What interventions are being tested in trial NCT05041127?
The interventions under investigation include: Cetuximab (BIOLOGICAL), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT05041127?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05041127 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chordoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05041127's enrollment target sits among peer trials
29 10th of 15 higher than 6 of 15 other Chordoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chordoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pembrolizumab and Pemetrexed for Progressive Chordoma
RECRUITING · Phase 2
-
Proton Beam Therapy for Chordoma Patients
ACTIVE NOT RECRUITING · Phase 2
-
Children and Adults With Chordoma
RECRUITING
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
RECRUITING · Phase 1
-
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI